Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | XBP1 | P17861 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4677894 | 0.82 | MAPT (0.58) | MAPTPOLBRAB9AKMT2A | |
| SCHEMBL11888034 | 0.82 | RAB9A (0.43) | MAPTPOLBRAB9AXBP1NPSR1 | |
| SCHEMBL2691331 | 0.82 | CYP2A6 (0.50) | MAPTPOLBRAB9A | |
| SCHEMBL11886178 | 0.81 | MAPT (0.51) | MAPTPOLBRAB9AXBP1NPSR1 | |
| SCHEMBL13975027 | 0.80 | MAPT (0.69) | MAPTPOLBRAB9AXBP1NPSR1 | |
| SCHEMBL19936442 | 0.80 | NPY5R (0.47) | MAPTPOLBRAB9A | |
| SCHEMBL11888048 | 0.80 | RAB9A (0.46) | MAPTRAB9AKMT2APHGDH | |
| SCHEMBL15656086 | 0.80 | MAPT (0.64) | MAPTPOLBRAB9AXBP1NPSR1 | |
| SCHEMBL13975008 | 0.78 | MAPT (0.63) | MAPTPOLBRAB9AXBP1NPSR1 | |
| SCHEMBL5306582 | 0.78 | MAPT (0.41) | MAPTPOLBRAB9AXBP1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024107658-A2 | INHIBITORS OF TYK2 | VYRNWY THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| CN-115996910-A | Aryl or heteroaryl derivatives | 帝人制药株式会社 | 2023-04-21 | — | — | CN | disclosed |
| EP-2078002-B1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8476278-B2 | Thiazole Derivatives as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8227605-B2 | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors | SCHERING CORPORATION (US) | 2012-07-24 | — | — | US | disclosed |
| US-20100331313-A1 | Thiazole Derivatives as Protein Kinase Inhibitors | SCHERING CORPORATION | 2010-12-30 | — | — | US | disclosed |
| US-20100055090-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-03-04 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| WO-2009077844-A2 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | QUONOVA LLC (US) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077844-A2 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | QUONOVA LLC (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331313-A1 | Thiazole Derivatives as Protein Kinase Inhibitors | DAPK2, DAPK1, JAK1 | MAPT 503/4885POLB 3242/4885RAB9A 4082/4885 |
| US-20100055090-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MAPK15, CDK15, MAP3K15 | MAPT 469/4885POLB 2101/4885RAB9A 4517/4885 |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | PGLS, TFPI, Q6ZSR9 | MAPT 3184/4885POLB 1144/4885RAB9A 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.